Medical Center Haaglanden
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Medical Center Haaglanden, researchers are investigating atherosclerotic cardiovascular disease and the role of elevated lipoprotein(a) in heart health. The trials aim to test new lipid‑lowering therapies and determine whether they can reduce major adverse cardiovascular events such as heart attacks and strokes.
- Evaluation of obicetrapib for ASCVD patients
- Olpasiran’s effect on Lp(a) reduction
- Impact on cardiovascular event rates
- Safety of novel lipid‑modifying agents
- Long‑term outcomes in high‑risk populations
With 38 investigators leading 7 active studies, the site combines cardiology expertise and advanced imaging to improve prevention strategies for patients across the Netherlands.
Female Urogenital Diseases and Pregnancy Complications
The centre’s reproductive health program focuses on women experiencing unexplained subfertility and recurrent pregnancy loss. Clinical trials are testing whether adding progesterone support or low‑dose prednisolone can increase the chance of a live birth in couples undergoing assisted conception.
- Progesterone luteal phase support in IUI cycles
- Cost‑effectiveness of mild ovarian stimulation protocols
- Prednisolone treatment for recurrent miscarriage
- Live‑birth rate as primary outcome
- Hormonal optimization for early pregnancy
The multidisciplinary team of obstetricians, endocrinologists and fertility specialists collaborates to translate these findings into everyday clinical practice.
Neoplasms
Oncology research at the hospital targets aggressive cancers such as Diffuse Large B‑Cell Lymphoma and metastatic castration‑resistant prostate cancer. Trials evaluate the addition of immunotherapies to standard chemotherapy to improve survival and delay disease progression.
- Epcoritamab combined with R‑CHOP in newly diagnosed DLBCL
- Pembrolizumab plus enzalutamide versus enzalutamide alone
- Progression‑free survival as primary endpoint
- Overall survival and radiographic response assessment
- Biomarker‑driven patient selection
The oncology department works closely with academic partners to bring cutting‑edge immuno‑oncology treatments to patients in the region.
Reproductive and Urinary Physiological Phenomena
This research stream explores the underlying physiological mechanisms of fertility and urinary health, aiming to improve diagnostic tools and therapeutic options for conditions such as unexplained infertility and hormonal imbalance.
- Hormonal stimulation protocols for IUI
- Biomarker analysis of luteal phase adequacy
- Evaluation of uterine environment in early pregnancy
- Integration of urinary biomarkers in reproductive assessment
- Translational studies linking physiology to clinical outcomes
By linking basic science with patient‑centered trials, the department seeks to enhance fertility care and reduce miscarriage rates for women served by the Medical Center Haaglanden.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 271 other sites in The Netherlands
Therapeutic Area Benchmark — The Netherlands
Select a therapeutic area to compare against other sites in The Netherlands.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: The Netherlands
Market Share
Country: The Netherlands
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Haaglanden
lock Showing 1 of 8 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641) | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2019 | Aug 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alteplase | 1 | Unknown | 2025-08-04 | 2025-08-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.